Adenocarcinoma of Pancreas
Conditions
Brief summary
A pilot randomized feasibility trial with a blinded evaluator.
Detailed description
Chemotherapy-induced peripheral neuropathy (CIPN) has a dose limiting effect which can greatly affect quality of life and often limits the amount of treatment patients can receive in treating their cancer. In the discipline of hand therapy, there is a science-based body of knowledge with effective protocols to treat neuropathies associated with injury and disease. These interventions have not been explored on patients with CIPN.
Interventions
OTHERHand Therapy Until CIPN
Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
OTHERTraditional Occupational Therapy (TOT)
Traditional occupational therapy intervention targeting compensatory strategies (TOT)
Sponsors
HonorHealth Research Institute
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with adenocarcinoma of the pancreas who will receive chemotherapy with albumin bound paclitaxel plus gemcitabine containing combination 2. Patients who have no prior evidence of peripheral neuropathy of the hands 3. Age 18 years or older 4. Able to sit for minimum of 30 minutes for hand therapy sessions
Exclusion criteria
1. Patients who have received at least one dose of chemotherapy with albumin bound paclitaxel plus gemcitabine during the past 6 months 2. Patients taking duloxetine or gabapentin 3. History of peripheral neuropathy of the hands due to chemotherapy, diabetes, or other causes 4. Inability to sit for minimum of 30 minutes 5. Documented cognitive problems limiting ability to participate in hand therapy
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORGayle Jameson
HonorHealth Research Institute
Outcome results
None listed